Discussion about this post

User's avatar
Molecule Trader's avatar

Really enjoyed this, Andrii. The Biossil section makes you wonder how many potentially useful treatments we’ve shelved because we couldn’t identify who would benefit. I’d love to see AI get good enough at that to help select patients before a trial begins, as well as revisit drugs afterwards. There’s something quite hopeful about the possibility that a treatment someone needs has already been developed and is sitting on a shelf. Looking forward to seeing how these programs progress.

Jillian Berk's avatar

The interesting variable is the purchase price. A failed asset is sold by a company that has already written it off, so the buyer acquires the molecule, the safety data and years of development at the price of a disappointment. Even if the subgroup thesis is often wrong, the cost basis carries the trade. The seller is not parting with a drug. It is parting with a line it no longer wants to explain to its board.

6 more comments...

Ready for more?